Kerala acute heart failure registry—Rationale, design and methods

Joseph, Stigi; Abdullakutty, Jabir; Sanjay, G.; Jeemon, Panniyammakal; Anwar, Chairanisa; Harikrishnan, S

doi:10.1016/j.ihj.2018.02.001

Cited by 6 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To better understand the current state of HF surveillance, we asked participating registry leaders to provide current demographic data of enrolled participants and case report form details. 5,8–29 The Figure shows an overview of selected registries, led by investigators participating in this viewpoint, which were largely region-specific (eg, Asian Sudden Cardiac Death in Heart Failure, The European Society of Cardiology Heart Failure Long-Term Registry, the Sub-Saharan Africa Survey of Heart Failure, Gulf CARE), country-specific (eg, Get With The Guidelines-Heart Failure, Change the Management of Patients With Heart Failure registry, National Cardiovascular Data Registry Practice Innovation and Clinical Excellence, Indian National HF Registry) or state/city-specific (eg, Kerala HF Registry, Trivandrum HF Registry) and include participants from each World Health Organization region. We acknowledge that this is not a comprehensive listing of all available registries, but a selected group.…”

Section: Etiologies Comorbidities and Case Definitions Of Hfmentioning

confidence: 99%

Toward a Universal Definition of Etiologies in Heart Failure: Categorizing Causes and Advancing Registry Science

Agarwal,

Tromp,

Almahmeed

et al. 2024

Circ: Heart Failure

View full text Add to dashboard Cite

Heart failure (HF) is a well-described final common pathway for a broad range of diseases however substantial confusion exists regarding how to describe, study, and track these underlying etiologic conditions. We describe (1) the overlap in HF etiologies, comorbidities, and case definitions as currently used in HF registries led or managed by members of the global HF roundtable; (2) strategies to improve the quality of evidence on etiologies and modifiable risk factors of HF in registries; and (3) opportunities to use clinical HF registries as a platform for public health surveillance, implementation research, and randomized registry trials to reduce the global burden of noncommunicable diseases. Investment and collaboration among countries to improve the quality of evidence in global HF registries could contribute to achieving global health targets to reduce noncommunicable diseases and overall improvements in population health.

show abstract

Section: Etiologies Comorbidities and Case Definitions Of Hfmentioning

confidence: 99%

Toward a Universal Definition of Etiologies in Heart Failure: Categorizing Causes and Advancing Registry Science

Agarwal,

Tromp,

Almahmeed

et al. 2024

Circ: Heart Failure

View full text Add to dashboard Cite

show abstract

“…The KHFR study also found that boosting GDMT prescription for HF through focused hospital-based quality improvement activities may increase survival rates both during and after hospitalization in India. 18,19…”

Section: Prove-hf Study: Prospective Study Of Biomarkers Symptom Impr...mentioning

confidence: 99%

The Power and Promise of Angiotensin Receptor Neprilysin Inhibitor (ARNI) in Heart Failure Management: National Consensus Statement

Chopra¹,

Wander²,

Ponde³

et al. 2023

JAPI

View full text Add to dashboard Cite

Heart failure (HF) is a huge global public health task due to morbidity, mortality, disturbed quality of life, and major economic burden. It is an area of active research and newer treatment strategies are evolving. Recently angiotensin receptor-neprilysin inhibitor (ARNI), a class of drugs (the first agent in this class, Sacubitril–Valsartan), reduces cardiovascular mortality and morbidity in chronic HF patients with reduced left ventricular ejection fraction (LVEF). Positive therapeutic effects have led to a decrease in cardiovascular mortality and HF hospitalizations (HFH), with a favorable safety profile, and have been documented in several clinical studies with an unquestionable survival benefit with ARNI, Sacubitril–Valsartan. This consensus statement of the Indian group of experts in cardiology, nephrology, and diabetes provides a comprehensive review of the power and promise of ARNI in HF management and an evidence-based appraisal of the use of ARNI as an essential treatment strategy for HF patients in clinical practice. Consensus in this review favors an early utility of Sacubitril–Valsartan in patients with HF with reduced EF (HFrEF), regardless of the previous therapy being given. A lower rate of hospitalizations for HF with Sacubitril–Valsartan in HF patients with preserved EF who are phenotypically heterogeneous suggests possible benefits of ARNI in patients having 40–50% of LVEF, frequent subtle systolic dysfunction, and higher hospitalization risk

show abstract

“… 6 The ongoing Kerala HF registry also has completed the recruitment of 7500 patients. 7 Another registry from a hospital in the National capital region included over 6000 HFrEF patients. 8 The available data from these registries show that HF patients in India are younger by 10-years, and the majority of the burden lies below 65years of age, as compared to the patients from high-income countries.…”

Section: Introductionmentioning

confidence: 99%

National Heart Failure Registry, India: Design and methods

Harikrishnan

Bahl

Roy

et al. 2019

Indian Heart Journal

View full text Add to dashboard Cite

Objective Heart failure (HF) has emerged as a global public health problem that affects both low and high-income countries. The high HF burden and the need for resource-intensive treatments often lead to health system crisis in resource-poor settings. Data on prevailing practice patterns and long-term clinical outcomes of HF are scarce from the low and middle-income countries. Nationally representative HF data from India are not available. Methods The National Heart Failure Registry (NHFR) is a multicentric, hospital-based registry of HF patients from 53 centers across India. Consecutive patients admitted with the diagnosis of acute decompensated HF satisfying the European Society of Cardiology (ESC) 2016 criteria will be enrolled into the registry from January 2019 to December 2019. Each participating center is expected to contribute 200 patients into the registry (i.e., more than 10,000 HF patients from India). We are collecting demographics, clinical, laboratory, imaging, and other diagnostic data at baseline from all registered patients in the registry by using a structured document. Additionally, we are collecting the details of treatment practices and the usage of guideline-directed therapy from all participants. We intend to obtain the in-hospital, 3-months, 6-months and one-year outcome data on mortality, cause of death, and repeated hospitalization events. Conclusions In summary, NFHR will be the first nationally representative HF registry aimed at providing crucial information on prevailing etiology, distribution and current practices in the management of HF.

show abstract

Kerala acute heart failure registry—Rationale, design and methods

Cited by 6 publications

References 16 publications

Toward a Universal Definition of Etiologies in Heart Failure: Categorizing Causes and Advancing Registry Science

Toward a Universal Definition of Etiologies in Heart Failure: Categorizing Causes and Advancing Registry Science

The Power and Promise of Angiotensin Receptor Neprilysin Inhibitor (ARNI) in Heart Failure Management: National Consensus Statement

National Heart Failure Registry, India: Design and methods

Contact Info

Product

Resources

About